

Thyromet: Shaping the Future of Thyroid Cancer with Epigenetics



OVERVIEW

Differentiated thyroid cancer (DTC) is the fastest-growing cancer, with 23% of patients developing distant metastases (DM). The Thyromet project, aims to predict DM risk early using a DNA methylation test and risk model. This will help personalize treatment, reduce overtreatment and lower healthcare costs by improving risk stratification and targeting high-risk patients.



PROJECT

Sector: Oncology, Endocrinology

R&D direction:

Detection and prognosis of thyroid cancer DTC

Stage of development: TRL2-3

Scientific leader: Dr. Mireia Jordà



PRODUCT

Potential indications:

Thyroid Cancer

Mechanism of action:

Usage of DNA methylation biomarker to predict the risk of DTC

Market Size: €3B in 2023



IP PROTECTION

Patent filed



OPPORTUNITY

License out

Spin-off generation

Co-development



NEED

Thyroid cancer is increasingly common, representing the 9th cancer globally with **550.000 new cases yearly**. Standard treatment is based on surgery, radioiodine and hormone therapy with patients falling into two groups: those with a clear prognosis at diagnosis and those with unpredictable outcomes (>80%). In this sense, up to **23% of patients progress** to distant metastases which are often fatal.



SOLUTION

Thyromet is an IVD test which utilizes DNA methylation biomarkers to predict metastasis risk in thyroid cancer patients. This allows for personalized treatment plans, timely interventions and minimize overtreatment, leading to better patient outcomes, improved quality of life and reduced healthcare costs.



KEY ADVANTAGES

- ✓ Early metastasis prediction: enables timely identification of high-risk patients.
- ✓ Personalized treatment: customizes surgeries and therapies based on individual risk profiles.
- ✓ Prevents overtreatment: reduces unnecessary interventions for low-risk patients.
- ✓ Cost reduction: optimizes healthcare resource use, leading to lower overall costs.

CONTACT US!

innovation@igtp.cat

Innovation & Business Development Unit



Germans Trias i Pujol Research Institute